US Pharma MarketingThe post Revolution’s RAS inhibitor pipeline posts more pancreatic cancer trial wins appeared first on Clinical Trials Arena.
Revolution’s RAS inhibitor pipeline posts more pancreatic cancer trial wins
The biotech’s G12D-selective RAS blocker has demonstrated its first and second-line combinatory potential in pancreatic cancer. The biotech’s G12D-selective RAS blocker has demonstrated its first and second-line combinatory potential in pancreatic cancer. Revolution Medicines’ zoldonrasib has demonstrated potential as a combinatory agent in both the frontline and refractory pancreatic cancer settings. Credit: e-crow / Shutterstock.com. Revolution Medicines has posted positive clinical results from a duo of studies evaluating its Rat sarcoma (RAS)-targeting therapies – potentially teeing the company up for movement into late-stage pipeline development efforts. In the ongoing Phase I/II RMC-GI-102 study (NCT06445062), the California-based biotech is evaluating its…
The biotech’s G12D-selective RAS blocker has demonstrated its first and second-line combinatory potential in pancreatic cancer.
Source: Clinical Trials Arena